Aarti Pharmalabs Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2fh91d1pu39s2hx76jyobrhi.pdf

Key Takeaways


Xanthine: Market Structure & Margin Strategy

Rashesh Gogri: "The way in which, the strategy that we have is that, how do we go away more from spot and move towards more long term market and regulated market, and which can give us stable margins and we don't have to fight on the spot side."

CDMO/CMO: Delays, Visibility & the H2 Bet

Rashesh Gogri: "Overall, the number that we had earlier mentioned about the 25% growth, we are pushing our team to get that growth. But however, this shift by one or two months can change that number by 5% to 7% also on the lower side."

Capacity Expansion: The FY27 Heavy Lifting


API & Margin Performance


Regulatory & Customer Milestones


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA growth10–12% growth in FY25; H1 at ₹197 crore, on track for ~₹230 crore in H2FY25
Long-term EBITDA growthAbout 15% annual growthNext year onward
Xanthine capacityIncremental capacity operational; entire project complete by Q3End of next fiscal; Q3 next financial year
Xanthine regulatory filingsFile USFDA DMF and EUGMP CEPLater in current fiscal
Xanthine regulatory approvalsBoth approvals and triggering expectedNext year
Atali greenfield commissioningCommissioning expectedQ4 FY25
Atali full operationalization~24 months from today~FY27
FY27 capacity contributionBulk of capacity operationalized, meaningful margins drivenFY27
Xanthine pharma mix target20% of capacity to regulated pharma, 5–10% to non-regulated pharmaOnce capacity ramped up
FY26 guidanceWill provide in Q4 call after budget finalizedQ4 FY25 call

Key Metrics

MetricQ2 FY25
Consolidated revenue (H1 FY25)₹1,014 cr, +13% YoY
Consolidated EBITDA from operations (H1 FY25)₹197 cr, +13% YoY
Consolidated PAT (H1 FY25)₹110 cr, +11% YoY
Standalone EBITDA margin23%, improved from 21%
Standalone gross margin55%
Overall gross margin65%, ranging 35% to 65% across segments
EBITDA growth guidance (FY25)10% to 12%, reaffirmed
Long-term annual EBITDA growth outlook~15% for next few years
API and Intermediate business revenue share51% of Q2 turnover
API and Intermediate regulated market share43% of sub-segment revenue
CDMO/CMO revenue share3% of Q2 turnover
CDMO/CMO revenue (FY24)₹167 cr
CDMO/CMO revenue (H1 FY25)~₹50 cr
CDMO/CMO growth guidance (FY25)~20%, revised from 25% due to spillover
CDMO/CMO active projects55 projects with 19 customers; 28 commercial, 27 developmental
CDMO/CMO innovator share90% of projects with innovators
Xanthine plant utilizationNear full capacity in Q2
Xanthine capacity expansion target9,000 metric tonnes per annum, from 5,000
Xanthine peak revenue potential at 9,000 tonnes$100–$150 million
Xanthine expansion CAPEX₹150 cr, inclusive of land
Xanthine global capacity share12%–15% of 40,000–50,000 tonnes total
Xanthine exportsMore than 50%
H1 FY25 CAPEX (tangible assets)₹170 cr
H2 FY25 planned CAPEX~₹250 cr
Overall CAPEX plan₹550–600 cr, unchanged
Atali greenfield project commissioningQ4 FY25 expected; full utilization in ~24 months